




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Letter to the Editor: Can the seasonal influenza vaccine for 2019/2020 have cross reactivity with some of the SARS-CoV-2 proteins?



Dear Editor,

Since December 2019, when severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged, several studies have examined the similarities and differences between SARS-CoV-2 and influenza viruses. In a recent study by Ilic et al., which was published in *International Journal of Infectious Diseases*, the authors stated that SARS-CoV-2 has an hemagglutinin-esterase (HE) glycoprotein. This study also suggested that the seasonal influenza vaccine for 2019/2020, which contained three or four strains of influenza A and B viruses, may have had cross reactivity with some SARS-CoV-2 proteins (Ilic et al., 2021); however, the proteins of these two different viruses are not the same.

The SARS-CoV-2 and influenza viruses are both enveloped with an encapsulated single-stranded RNA genome. However, their genomes vary in terms of polarity and segmentation. Influenza viruses have 7–8 segmented, negative-sense, single-stranded RNA genomes, while the SARS-CoV-2 genome comprises a non-segmented, positive-sense, single-stranded RNA (Pormohammad et al., 2020).

The *Orthomyxoviridae* family contains three major viruses: influenza types A, B and C. Influenza C carries seven encapsulated segments of negative-sense genomes encoding its structural proteins and non-structural proteins. It can encode a single envelope glycoprotein, named hemagglutinin-esterase-fusion factor (HEF), which is a single multifunction protein and plays a key role in attachment, fusion and receptor destruction. Influenzas A and B comprise eight encapsulated genomic segments and can encode two membrane glycoproteins: haemagglutinin (HA) and neuraminidase (NA). HA plays a key role in attachment and fusion, and NA plays an important role in receptor destruction and release of virions (Wang and Veit, 2016).

SARS-CoV-2 is a member of the *Coronaviridae* family; this viral family has four genera: alpha-coronavirus, beta-coronavirus, gamma-coronavirus and delta-coronavirus (Hosseini et al., 2021). The beta-coronavirus genus comprises five sub-genera: *Embecovirus* or lineage A (OC43-CoV, HKU1-CoV); *Sarbecovirus* or lineage B (SARS-CoV-2, SARS-CoV); *Merbecovirus* or lineage C (MERS-CoV); *Nobecovirus* or lineage D; and *Hibecovirus* (Decaro and Lorusso, 2020). Among beta-coronaviruses, only beta-coronaviruses lineage A, such as OC43-CoV, encodes HE (Kim, 2020). The HE gene has been transferred to beta-coronavirus lineage A through horizontal gene transmission from an HEF of influenza C (Kim, 2020).

In conclusion SARS-CoV-2, like SARS-CoV, lacks the HE gene (Kumar et al., 2020, To et al., 2021, Chan et al., 2020) and it has four structural proteins: spike (S), envelope (E), nucleoprotein (N) and membrane (M) (Troyano-Hernández et al., 2021); therefore, the

seasonal influenza vaccine for 2019/2020 could not have had cross-reactivity with some of the SARS-CoV-2 proteins.

Conflict of Interest

None.

Funding Source

None.

Ethical Approval

None.

References

- Ilic I, Zdravkovic M, Timcic S, Stojanovic DU, Bojic M, Loncar G. Pneumonia in healthcare workers during a COVID-19 outbreak at a cardiovascular hospitals. *International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases* 2021;103:188–93.
- Pormohammad A, Ghorbani S, Khatami A, Razizadeh MH, Alborzi E, Zarei M, et al. Comparison of influenza type A and B with COVID-19: A global systematic review and meta-analysis on clinical, laboratory and radiographic findings. *Reviews in medical virology* 2020:e2179.
- Wang M, Veit M. Hemagglutinin-esterase-fusion (HEF) protein of influenza C virus. *Protein & cell* 2016;7(1):28–45.
- Hosseini P, Afzali S, Karimi M, Zandi M, Zebardast A, Latifi T, et al. The coronavirus disease 2019 and effect on liver function: a hidden and vital interaction beyond the respiratory system. *Reviews in Medical Microbiology* 2021.
- Decaro N, Lorusso A. Novel human coronavirus (SARS-CoV-2): A lesson from animal coronaviruses. *Veterinary microbiology* 2020.
- Kim C-H. SARS-CoV-2 evolutionary adaptation toward host entry and recognition of receptor O-Acetyl sialylation in virus–host interaction. *International journal of molecular sciences* 2020;21(12):4549.
- Kumar S, Nyodu R, Maurya VK, Saxena SK. Morphology, genome organization, replication, and pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Coronavirus Disease 2019 (COVID-19): Springer* 2020:23–31.
- To KK-W, Sridhar S, Chiu KH-Y, Hung DL-L, Li X, Hung IF-N, et al. Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. *Emerging microbes & infections* 2021;10(1):507–35.
- Chan JF-W, Kok K-H, Zhu Z, Chu H, To KK-W, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. *Emerging microbes & infections* 2020;9(1):221–36.
- Troyano-Hernández P, Reinosa R, Holguín Á. Evolution of SARS-CoV-2 envelope, membrane, nucleocapsid, and spike structural proteins from the beginning of the pandemic to September 2020: a global and regional approach by epidemiological week. *Viruses* 2021;13(2):243.

Milad Zandi*

Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran

Emad Behboudi

Department of Microbiology, Golestan University of Medical Sciences,
Gorgan, Iran

Saber Soltani

Department of Virology, School of Public Health, Tehran University of
Medical Sciences, Tehran, Iran
Research Center for Clinical Virology, Tehran University of Medical
Sciences, Tehran, Iran

*Corresponding author: Department of Virology, School of
Public Health, Tehran University of Medical Sciences, Tehran,
Iran. Tel: +989372876578.

E-mail address: Miladzandi416@gmail.com (M. Zandi)